Dr Reona Sakemura Discusses Barriers to the Success of CAR T-Cell Therapies
Toxicities like cytokine release syndrome, along with other factors, limit widespread use of CAR T-cell therapies, said Reona Sakemura, MD, PhD, postdoctoral researcher at the Mayo Clinic.
Toxicities like cytokine release syndrome, along with other factors, limit widespread use of CAR T-cell therapies, said Reona Sakemura, MD, PhD, postdoctoral researcher at the Mayo Clinic.
Transcript
What are some of the barriers that are limiting the success of CAR T-cell therapies?
So, the widespread use of CAR T-cell therapy is limited due to lingering toxicities such as cytokine release syndrome, CRS, or neurotoxicity. Also, another limiting factor is CAR T-cell dysfunction, such as the poor T-cell expansions or poor traffic into tumor size, which is led by the bidirectional interaction between the tumor cells into a micro environment.
As CAR T-cell therapies are being used more, how has management of cytokine release syndrome improved?
The current way to manage Cytokine Release Syndrome, neurotoxicity, is the use of IL-6 receptor blockade, along with steroids. Early this year, we published that the perfect use of germs is neutralizing antibodies to not only prevent CRS but also to prevent the neurotoxicity in our mouse model. We're currently expanding this to a phase 2 clinical trial.
Transplant Eligibility Versus CAR-T Eligibility
January 16th 2025Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado, discussed the importance of referring patients with r/r LBCL who are transplant ineligible for CAR-T treatment.
Sequencing of Treatment in Third-Line R/R LBCL
January 15th 2025Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado, discussed the choice between treating patients with liso-cel or bispecific T-cell engagers.
